Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Leases (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Current Leases for 7 consecutive years, with $10.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 160.1% to $10.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.9 million, a 160.1% increase, with the full-year FY2024 number at $10.7 million, changed N/A from a year prior.
  • Current Leases was $10.9 million for Q3 2025 at Theravance Biopharma, roughly flat from $10.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $10.9 million in Q3 2025 to a low of $692000.0 in Q3 2022.
  • A 5-year average of $5.9 million and a median of $4.2 million in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 89.51% in 2021, then surged 1303.61% in 2023.
  • Theravance Biopharma's Current Leases stood at $1.0 million in 2021, then skyrocketed by 564.67% to $6.8 million in 2022, then skyrocketed by 43.83% to $9.7 million in 2023, then increased by 10.29% to $10.7 million in 2024, then rose by 1.89% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Current Leases are $10.9 million (Q3 2025), $10.9 million (Q2 2025), and $10.8 million (Q1 2025).